26 years of historical data (1999–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sangamo Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $92M | $206M | $95M | $485M | $1.1B | $2.1B | $938M | $1.1B | $1.3B | $215M | $637M |
| Enterprise Value | $81M | $194M | $88M | $427M | $953M | $2.0B | $902M | $1.0B | $1.3B | $197M | $567M |
| P/E Ratio → | -0.88 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.59 | 3.56 | 0.54 | 4.35 | 9.79 | 17.75 | 9.16 | 13.18 | 35.02 | 11.10 | 16.11 |
| P/B Ratio | 3.83 | 9.04 | 1.14 | 1.64 | 2.89 | 4.22 | 2.17 | 3.03 | 6.82 | 1.58 | 3.31 |
| P/FCF | — | — | — | — | — | 13.52 | — | — | 172.40 | — | — |
| P/OCF | — | — | — | — | — | 12.35 | — | 29.95 | 114.55 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.36 | 0.50 | 3.84 | 8.61 | 17.00 | 8.81 | 11.84 | 34.33 | 10.16 | 14.35 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 12.95 | — | — | 169.02 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Sangamo Therapeutics, Inc. earns an operating margin of -179.9%. A negative ROE of -185.4% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 89.1% | 100.0% | -52.8% | -42.5% | -36.0% | -79.7% | -238.4% | -69.8% |
| Operating Margin | -179.9% | -179.9% | -155.5% | -180.8% | -165.6% | -109.6% | -102.7% | -91.4% | -154.1% | -374.2% | -118.5% |
| Net Profit Margin | -169.4% | -169.4% | -146.3% | -172.8% | -161.1% | -102.4% | -92.9% | -80.9% | -149.2% | -369.6% | -102.9% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -185.4% | -185.4% | -136.5% | -57.4% | -40.9% | -26.0% | -23.8% | -24.6% | -33.7% | -43.6% | -20.4% |
| ROA | -73.4% | -73.4% | -70.8% | -29.9% | -21.5% | -15.4% | -15.5% | -15.6% | -24.5% | -38.2% | -17.7% |
| ROIC | -178.8% | -178.8% | -131.1% | -62.6% | -42.1% | -24.1% | -24.2% | -27.7% | -30.1% | -45.2% | -21.7% |
| ROCE | -119.9% | -119.9% | -96.4% | -38.5% | -26.4% | -19.0% | -19.5% | -20.5% | -29.2% | -42.5% | -22.3% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $42M exceeds total debt of $31M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.34 | 1.34 | 0.46 | 0.15 | 0.13 | 0.08 | 0.10 | 0.08 | 0.13 | 0.03 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.50 | -0.09 | -0.19 | -0.35 | -0.18 | -0.08 | -0.31 | -0.13 | -0.13 | -0.36 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -0.58 | — | — | -3.38 | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($42M) exceeds total debt ($31M)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.13x means Sangamo Therapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.69x to 1.13x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.13 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 | 5.80 | 5.23 | 5.54 | 11.25 | 10.58 |
| Quick Ratio | 1.13 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 | 5.80 | 5.23 | 5.57 | 11.27 | 10.59 |
| Cash Ratio | 0.92 | 0.92 | 1.70 | 2.49 | 2.94 | 4.47 | 5.19 | 5.10 | 5.42 | 10.72 | 10.40 |
| Asset Turnover | — | 0.57 | 1.07 | 0.20 | 0.15 | 0.13 | 0.16 | 0.14 | 0.13 | 0.12 | 0.18 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 29.04 | 8.42 | 14.67 | 20.98 | 19.33 | 133.95 | 21.82 | 35.76 | 97.82 | 26.11 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sangamo Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 7.4% | — | — | 0.6% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $202M | $174M | $154M | $145M | $134M | $112M | $97M | $78M | $71M | $70M |
Compare SGMO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SGMOYou | $92M | -0.9 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SGMO stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonSangamo Therapeutics, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
Sangamo Therapeutics, Inc.'s return on equity (ROE) is -185.4%. The historical average is -44.1%.
Based on historical data, Sangamo Therapeutics, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Sangamo Therapeutics, Inc. has 100.0% gross margin and -179.9% operating margin.